GWM
NGNE icon

Geneos Wealth Management’s Neurogene NGNE Stock Holding History

Geneos Wealth Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11
Closed -$2K – 2882
2021
Q2 		$2K Hold
11
– – ﹤0.01% 2673
2021
Q1 		$2K Hold
11
– – ﹤0.01% 2909
2020
Q4 		$2K Hold
11
– – ﹤0.01% 2709
2020
Q3 		$2K Hold
11
– – ﹤0.01% 2429
2020
Q2 		$3K Hold
11
– – ﹤0.01% 2290
2020
Q1 		$2K Hold
11
– – ﹤0.01% 2274
2019
Q4 		$2K Buy
+11
New +$1.1K ﹤0.01% 2386

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Geneos Wealth Management's NGNE Position: Q3 2021 in Review

Geneos Wealth Management sold out of Neurogene (NGNE) in Q3 2021, closing a stake of 11 shares — an estimated $2K sold.

Geneos Wealth Management first reported a position in NGNE in Q4 2019 and held it in 7 quarters. The position peaked at $3K in Q2 2020. 85 funds tracked by Wall St. Rank hold NGNE as of Q3 2021.

  • Geneos Wealth Management reported no remaining Neurogene position as of Q3 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 11 Neurogene shares in Q3 2021, an estimated $2K.
  • Geneos Wealth Management first reported a position in Neurogene in Q4 2019 and held it in 7 quarters.
  • Geneos Wealth Management's Neurogene position peaked at $3K in Q2 2020.
  • 85 funds tracked by Wall St. Rank held Neurogene as of Q3 2021.

Based on Geneos Wealth Management's 13F filing for Q3 2021, filed 9 Nov 2021.